Axial Biotherapeutics Strengthens Regulatory Team with Appointment of Dr. Gregory Bates as Senior Vice President of Regulatory Affairs
BOSTON and Pasadena, Calif., November 02, 2017 – Axial Biotherapeutics, a biotechnology company building a unique class of microbial-targeted central nervous system (CNS) therapeutics, today announced the appointment of Dr. Gregory T. Bates as Senior Vice President of Regulatory Affairs. Dr. Bates will serve on the Axial senior management team and will be responsible for all aspects of regulatory support and operations, including the development of key regulatory strategies as the Company prepares for its lead candidates to enter the clinic. He will be based in Axial’s Boston office and will report to Chief Medical Officer, Srinivas Rao, M.D., Ph.D.
“Greg is an important addition to Axial’s management team as we continue advancing our lead programs in Autism Spectrum Disorder (ASD) and Parkinson’s Disease (PD) and prepare to enter the clinic in 2018,” said David H. Donabedian, Ph.D., Co-founder and CEO of Axial Biotherapeutics. “Greg possesses tremendous experience in overseeing successful regulatory programs in CNS diseases and disorders and a number of other therapeutic areas. We look forward to his insights in leading and implementing our regulatory strategies to rapidly bring microbial-targeted CNS therapeutics to patients.”
Gregory T. Bates, DVM joins Axial with thirty years of international pharmaceutical industry experience, including twenty-seven years in regulatory affairs covering the regulation of drugs and biologics. Prior to joining Axial, Dr. Bates served as Vice President of Regulatory Affairs at Depomed, Inc. (NASDAQ: DEPO), where he provided regulatory strategies for the product teams managing the Company’s development-stage and commercialized pain therapeutics and managed the Company’s regulatory affairs and regulatory operations staff. For 10 years, Dr. Bates was part of the senior management team at XenoPort, Inc. (NASDAQ: XNPT), including four years as Senior Vice President of Regulatory Affairs and Quality and successfully led the Company’s NDA and sNDA filings and approvals for its restless legs syndrome treatment drug, Horizant® (gabapentin enacarbil). Prior to XenoPort, Dr. Bates served as Director and Senior Director of Regulatory Affairs at Pharmacyclics, Inc., directing its regulatory operations group and coordinating communications with global regulatory agencies. His career is further highlighted by Regulatory Affairs positions at Genentech, Inc. and Syntex (U.S.A.), Inc. Dr. Bates received his Doctor of Veterinary Medicine (DVM) degree from the University of California, Davis and holds a bachelor’s degree in Human Physiology from the University of California, Berkeley.
About Axial Therapeutics
Axial Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-restricted, small molecule therapeutics for central nervous system (CNS) disorders. The company is leveraging its expertise in the gut-brain axis and its unique drug development platform to advance novel therapies that have the potential to transform the treatment paradigm in neurological diseases. Axial is advancing a pipeline of small molecule product candidates with lead clinical programs that address underlying pathology and resulting symptoms in Autism Spectrum Disorder (ASD) and Parkinson’s Disease (PD), and additional preclinical initiatives in small molecules in other areas of autism and PD, as well as oncology and rare CNS diseases.
Contacts for Axial Therapeutics
Sam Brown, Inc.
Jeffrey Young, CFO